Crossmark

Development of a set of bacterial engineered glycoconjugates as novel serogroup-specific antigens for the serodiagnosis of Escherichia coli O26, O111, O103 and O45 infections associated to hemolytic uremic syndrome

Crossref DOI link: https://doi.org/10.1186/s12934-025-02694-0

Published Online: 2025-05-20

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Caillava, Ana J.

Melli, Luciano J.

Landoni, Malena

Landivar, Stella Maris

Chinen, Isabel

Couto, Alicia S.

Rivas, Marta

Ugalde, Juan E.

Comerci, Diego J.

Ciocchini, Andrés E.
Funding

Funding for this research was provided by:

Consejo Nacional de Investigaciones Científicas y Técnicas
License Information

Text and Data Mining valid from 2025-05-20

Version of Record valid from 2025-05-20
More Information

Article History

Received: 2 October 2024

Accepted: 13 March 2025

First Online: 20 May 2025

Declarations

:

: Not applicable.

: Not applicable.

: A patent has been filed regarding the diagnostic application of recombinant glycoproteins.

Document is current

Any future updates will be listed below